Patents by Inventor Justian Craig Fox

Justian Craig Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TARGETING PULMONARY DISEASES WITH AGENTS THAT BIND A TARGET IN PULMONARY TISSUE
    Publication number: 20170210814
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed arc the use of agents a for the manufacture of a delivery device (e.g.
    Type: Application
    Filed: March 27, 2017
    Publication date: July 27, 2017
    Inventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
    Patent number: 9629909
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: April 25, 2017
    Assignee: Domantis Limited
    Inventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Inhaled combination therapy
    Patent number: 9084799
    Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 21, 2015
    Assignee: Pulmagen Therapeutics (Synergy) Limited
    Inventors: Justian Craig Fox, Mary Frances Fitzgerald, Harry Finch
  • METHODS FOR TARGETING PULMONARY DISEASES WITH AGENTS THAT BIND A TARGET IN PULMONARY TISSUE
    Publication number: 20130309227
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.
    Type: Application
    Filed: June 18, 2013
    Publication date: November 21, 2013
    Applicant: Domantis Limited
    Inventors: Rudolf M. T. De Wildt, Steve Holmes, Ian M. Tomlinson, Greogory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
    Patent number: 8497244
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: July 30, 2013
    Assignee: Domantis Limited
    Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases
    Patent number: 8431553
    Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.
    Type: Grant
    Filed: February 13, 2006
    Date of Patent: April 30, 2013
    Assignee: Pulmagen Therapeutics (Synergy) Limited
    Inventors: Justian Craig Fox, Mary Frances Fitzgerald, Harry Finch
  • Inhaled combination therapy
    Patent number: 8426393
    Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: April 23, 2013
    Assignee: Pulmagen Therapeutics (Synergy) Limited
    Inventors: Justian Craig Fox, Mary Frances Fitzgerald, Harry Finch
  • METHODS FOR TARGETING PULMONARY DISEASES WITH AGENTS THAT BIND A TARGET IN PULMONARY TISSUE
    Publication number: 20120114651
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.
    Type: Application
    Filed: January 23, 2012
    Publication date: May 10, 2012
    Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Agents that bind a target in pulmonary tissue for targeting respiratory diseases
    Patent number: 8129503
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: March 6, 2012
    Assignee: Domantis Limited
    Inventors: Rudolf M. T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Inhaled combination therapy
    Publication number: 20100324002
    Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.
    Type: Application
    Filed: August 24, 2010
    Publication date: December 23, 2010
    Inventors: Justian Craig Fox, Mary Frances Fitzgerald, Harry Finch
  • Agents that Bind a Target in Pulmonary Tissue for Targeting Respiratory Diseases
    Publication number: 20100034831
    Abstract: Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g.
    Type: Application
    Filed: October 23, 2006
    Publication date: February 11, 2010
    Inventors: Rudolf M.T. de Wildt, Steve Holmes, Ian M. Tomlinson, Gregory P. Winter, Mary F. Fitzgerald, Justian Craig Fox, Armin Sepp, Jennifer Luckett, Benjamin P. Woolven
  • Combination of Methylxanthine Compounds and Steroids to Treat Chronic Respiratory Diseases
    Publication number: 20080318913
    Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.
    Type: Application
    Filed: February 13, 2006
    Publication date: December 25, 2008
    Inventors: Justian Craig Fox, Mary Frances Fitzgerald, Harry Finch